E-ISSN: 2147-1959
Nasolacrimal Duct Obstruction on <sup>131</sup>I SPECT/CT: Atypical False-positive Paranasal Radioiodine Uptake as a Complication of Single-dose RAI Treatment
PDF
Cite
Share
Request
Interesting Image
VOLUME: 31 ISSUE: 3
P: 234-236
October 2022

Nasolacrimal Duct Obstruction on 131I SPECT/CT: Atypical False-positive Paranasal Radioiodine Uptake as a Complication of Single-dose RAI Treatment

Mol Imaging Radionucl Ther 2022;31(3):234-236
DOI: 10.4274/mirt.galenos.2021.68926
Nuh Filizoğlu 1
Kevser Öksüzoğlu 1
Salih Özgüven 1
Onur Buğdaycı 2
Tanju Yusuf Erdil 1
1. Marmara University, Pendik Training and Research Hospital, Clinic of Nuclear Medicine, İstanbul, Turkey
2. Marmara University, Pendik Training and Research Hospital, Clinic of Radiology, İstanbul, Turkey
No information available.
No information available
Received Date: 10.03.2021
Accepted Date: 08.07.2021
Publish Date: 19.10.2022
PDF
Cite
Share
Request

ABSTRACT

Nasolacrimal duct obstruction (NLDO) is a rare complication after radioiodine therapy and may cause false positive 131I uptake at the point of obstruction in 131I whole body scan. Here, we report a 59-year-old female patient with papillary thyroid cancer treated with total thyroidectomy followed by 131I therapy. 131I whole body scan revealed focal uptake in the head. Single photon emission computed tomography/computed tomography (CT) showed focal uptake at the right proximal nasolacrimal duct. The ophthalmologic examination and the diagnostic maxillofacial CT confirmed the diagnosis of NLDO.

References

1
Ali MJ. Iodine-131 Therapy and nasolacrimal duct obstructions: what we know and what we need to know. Ophthalmic Plast Reconstr Surg 2016;32:243-248.
2
Burns JA, Morgenstern KE, Cahill KV, Foster JA, Jhiang SM, Kloos RT. Nasolacrimal obstruction secondary to I(131) therapy. Ophthalmic Plast Reconstr Surg 2004;20:126-129.
3
Fard-Esfahani A, Mirshekarpour H, Fallahi B, Eftekhari M, Saghari M, Beiki D, Ansari-Gilani K, Takavar A. The effect of high-dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma. Clin Nucl Med 2007;32:696-699.
4
Morgenstern KE, Vadysirisack DD, Zhang Z, Cahill KV, Foster JA, Burns JA, Kloos RT, Jhiang SM. Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients. Ophthalmic Plast Reconstr Surg 2005;21:337-344.
5
Yuoness S, Rachinsky I, Driedger AA, Belhocine TZ. Differentiated thyroid cancer with epiphora: detection of nasolacrimal duct obstruction on I-131 SPECT/CT. Clin Nucl Med 2011;36:1149-1152.
6
Fard-Esfahani A, Farzanefar S, Fallahi B, Beiki D, Saghari M, Emami-Ardekani A, Majdi M, Eftekhari M. Nasolacrimal duct obstruction as a complication of iodine-131 therapy in patients with thyroid cancer. Nucl Med Commun 2012;33:1077-1080.
7
Brockmann H, Wilhelm K, Joe A, Palmedo H, Biersack HJ. Nasolacrimal drainage obstruction after radioiodine therapy: case report and a review of the literature. Clin Nucl Med 2005;30:543-545.
8
Ali MJ, Vyakaranam AR, Rao JE, Prasad G, Reddy PV. Iodine-131 therapy and lacrimal drainage system toxicity: nasal localization studies using whole body nuclear scintigraphy and SPECT-CT. Ophthalmic Plast Reconstr Surg 2017;33:13-16.